PATENT CLAIM ANALYSIS

Application Number: 15860145
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["424", "186100"]

Abstract:
An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.

Claim (Index 60):
A method of adoptive immunotherapy including the step of administering said CMV-specific CTLs produced at step (b) of  claim 59  to an animal to thereby prophylactically or therapeutically treat a CMV infection of said animal.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 86.0
- Lexical Diversity: 1.55128
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14436239', '11720421', '13334657', '12678046', '10168843']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7675909817133242
- 35 USC 102 Novelty (BERT): 0.6339085352013025
- Combined Prediction Score: 0.7542227370621221
- Mean Citation Score: 415.614268
- Max Citation Score: 699.9618
- Similarity Product: 526.1566846049667

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test